德康医疗 DXCM 深 沪
等待开盘 11-21 09:30:00 美东时间
58.42
-1.310
-2.19%
华盛通- 最 高60.755
- 今 开59.72
- 成交量 482.09万股
- 最 低 58.285
- 昨 收 59.73
- 总市值 229.01亿
- 52周最高 93.25
- 市盈率 静 41.03
- 换手率 1.23%
- 52周最低 54.11
- 委 比 19.90%
- 总股本 3.92亿
- 历史最高 164.863
- 量 比 0.77
- 振 幅 4.14%
- 历史最低 1.6875
- 每 手 1
- 风险率 8.58%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多DexCom Receives FDA Clearance For Its Dexcom Smart Basal Insulin Dosing Optimizer For Patients With Type 2 Diabetes
DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the FDA has cleared Dexcom Smart Basal, the first and only CGM-integrated basal insulin dosing optimizer designed for adults with Type
11-19 21:36
美股大行评级 | 花旗上调英伟达目标价从210美元升至220美元；DraftKings、DoubleVerify遭多家大行下调目标价
今日重点评级关注：Guggenheim：维持InflaRx"买入"评级，目标价从10美元升至22美元；巴克莱：维持Tandem糖尿病护理"超配"评级，目标价从51美元升至55美元
11-11 10:49
美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
11-10 17:17
Celldex Announces Appointment of Teri Lawver as Chief Commercial Officer
Celldex appointed Teri Lawver as Senior Vice President and Chief Commercial Officer. With over 30 years of experience in the biopharmaceutical and medical device sectors, Lawver succeeds Richard Wright, who is retiring after a decade at Celldex. Lawver's expertise in immunology and inflammation includes successful launches of key treatments, and she will oversee the potential launch of barzolvolimab and advance Celldex's pipeline. Wright's contri...
11-10 13:01
美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
11-10 10:22
Why TAL Education, Shake Shack And DexCom Just Appeared On Value Investors' Radars
A trio of stocks made an impressive leap in their Benzinga Edge value scores this week, with one standout making a 138% jump.
11-08 22:16
Argus Research Maintains Buy on DexCom, Lowers Price Target to $90
Argus Research analyst Steve Silver maintains DexCom (NASDAQ:DXCM) with a Buy and lowers the price target from $100 to $90.
11-08 00:42
美股大行评级 | 高盛上调英伟达目标价升至240美元； Loop Capital上调英伟达目标价升至350美元！
今日重点评级关注：花旗：维持Caribou Biosciences"买入"评级，目标价从5美元升至8美元；HC Wainwright & Co.：上调MoonLake Immunotherapeutics - Class A Ordinary Shares评级至"买入"，目标价30美元
11-04 10:31
DexCom Faces Class Action Over Alleged Investor Deception
In a dramatic turn of events, DexCom, Inc., a prominent player in the glucose m...
11-04 05:15
美股大行评级 | 苹果、亚马逊、Cloudflare、西部数据、Twilio等获十多家机构集体上调目标价；杰富瑞首予Cloudflare"持有"评级，目标价250美元
今日重点评级关注：康托·菲茨杰拉德：维持Cabaletta Bio"超配"评级，目标价从15美元升至30美元；HC Wainwright & Co.：维持Invivyd"买入"评级，目标价从5美元升至10美元
11-03 20:20
